Next Article in Journal
Extracellular DNA Correlates with Intestinal Inflammation in Chemically Induced Colitis in Mice
Previous Article in Journal
The Mitochondrial Permeability Transition: Nexus of Aging, Disease and Longevity
Article

SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells

1
Department of Urology, Jena University Hospital, 07740 Jena, Germany
2
RNA Bioinformatics and High-Throughput Analysis, Friedrich Schiller University Jena, 07743 Jena, Germany
3
Department of Forensic Medicine, Section of Pathology, Jena University Hospital, 07740 Jena, Germany
*
Author to whom correspondence should be addressed.
Current Address: Robert Koch Institute, MF1 Bioinformatics, 13353 Berlin, Germany.
Cells 2021, 10(1), 80; https://doi.org/10.3390/cells10010080
Received: 12 November 2020 / Revised: 29 December 2020 / Accepted: 30 December 2020 / Published: 6 January 2021
Bladder cancer is a very heterogeneous disease and the molecular mechanisms of carcinogenesis and progression are insufficiently investigated. From the DNA sequencing analysis of matched non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) samples from eight patients, we identified the tumour-associated gene SLC35F2 to be mutated in the 5′ and 3′ untranslated region (UTR). One mutation in 3′UTR increased the luciferase activity reporter, suggesting its influence on the protein expression of SLC35F2. The mRNA level of SLC35F2 was increased in MIBC compared with NMIBC. Furthermore, in immunohistochemical staining, we observed a strong intensity of SLC35F2 in single tumour cells and in the border cells of solid tumour areas with an atypical accumulation around the nucleus, especially in the MIBC. This suggests that SLC35F2 might be highly expressed in aggressive and invasive tumour cells. Moreover, knockdown of SLC35F2 repressed the growth of bladder cancer cells in the monolayer and spheroid model and suppressed migration and invasion of bladder cancer cells. In conclusion, we suggest that SLC35F2 is involved in bladder cancer progression and might provide a new therapeutic approach, for example, by the anti-cancer drug YM155, a cargo of the SLC35F2 transporter. View Full-Text
Keywords: bladder cancer; oncogene; SLC35F2; UTR mutation; progression bladder cancer; oncogene; SLC35F2; UTR mutation; progression
Show Figures

Figure 1

MDPI and ACS Style

Kotolloshi, R.; Hölzer, M.; Gajda, M.; Grimm, M.-O.; Steinbach, D. SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells. Cells 2021, 10, 80. https://doi.org/10.3390/cells10010080

AMA Style

Kotolloshi R, Hölzer M, Gajda M, Grimm M-O, Steinbach D. SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells. Cells. 2021; 10(1):80. https://doi.org/10.3390/cells10010080

Chicago/Turabian Style

Kotolloshi, Roland, Martin Hölzer, Mieczyslaw Gajda, Marc-Oliver Grimm, and Daniel Steinbach. 2021. "SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells" Cells 10, no. 1: 80. https://doi.org/10.3390/cells10010080

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop